Fox Run Management’s Oric Pharmaceuticals ORIC Stock Holding History

Fox Run Management’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,887	Closed	-$203K	–	1164
2025 Q3	$203K	Buy	+16,887	New	+$178K	0.03%	805

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fox Run Management's ORIC Position: Q4 2025 in Review

Fox Run Management sold out of Oric Pharmaceuticals (ORIC) in Q4 2025, closing a stake of 16,887 shares — an estimated $203K sold.

Fox Run Management first reported a position in ORIC in Q3 2025 and held it in 1 quarter. The position peaked at $203K in Q3 2025. 164 funds tracked by Wall St. Rank hold ORIC as of Q4 2025.

Fox Run Management reported no remaining Oric Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Fox Run Management sold 16,887 Oric Pharmaceuticals shares in Q4 2025, an estimated $203K.
Fox Run Management first reported a position in Oric Pharmaceuticals in Q3 2025 and held it in 1 quarter.
Fox Run Management's Oric Pharmaceuticals position peaked at $203K in Q3 2025.
164 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.